Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

BLINK CHARGING ANNOUNCES FIRST QUARTER 2025 RESULTS

First quarter 2025 total revenues of $20.8 millionFirst quarter 2025 service revenues grew 29.2% to $10.6 million compared to $8.2 million in first quarter of 2024Gross margin of 35.5% in the first quarter of 2025During the first quarter the Company added 319 Blink-owned chargers …

EODHD | 12 May 2025

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 …

EODHD | 12 May 2025

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am …

EODHD | 12 May 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

- Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET PASADENA, Calif., May 12, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call …

EODHD | 12 May 2025

Assertio Reports First Quarter 2025 Financial Results

First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or …

EODHD | 12 May 2025

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam logo CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) …

EODHD | 12 May 2025

Resolute Holdings Reports First Quarter 2025 Results

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company responsible for providing management services to CompoSecure Holdings, L.L.C. (“CompoSecure Holdings”), a wholly owned subsidiary of CompoSecure, Inc. (“CompoSecure”) (Nasdaq: CMPO), today reported financial …

EODHD | 12 May 2025

CompoSecure Reports First Quarter 2025 Financial Results

Operating results in line with expectationsReiterating previously issued full-year 2025 guidanceCompleted spin-off of Resolute Holdings Management, Inc. (Nasdaq: RHLD)Accounting standards related to the spin-off require the Company to report results using equity method of accounting in accordance with U.S. GAAPNon-GAAP results are also included …

EODHD | 12 May 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory …

EODHD | 12 May 2025

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s (PTABs) previous decision and remanded …

EODHD | 12 May 2025
Support

Hi! How can we help you today?

Loading…